Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 4, April, p. 449–453

doi: 10.17219/acem/75675

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Interleukin 6, osteoprotegerin, sRANKL and bone metabolism in inflammatory bowel diseases

Iwona Krela-Kaźmierczak1,A,B,C,D,E,F, Aleksandra Szymczak-Tomczak1,B,E, Liliana Łykowska-Szuber1,C,E, Ewa Wysocka2,B,C,E, Michał Michalak3,C,E,F, Kamila Stawczyk-Eder1,B,D, Katarzyna Waszak1,B,C, Krzysztof Linke1,E,F, Piotr Eder1,B,C,E,F

1 Department of Gastroenterology, Dietetics and Internal Medicine, Poznan University of Medical Sciences, Poland

2 Department of Laboratory Diagnostics, Poznan University of Medical Sciences, Poland

3 Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poland


Background. Cytokines are mediators of inflammatory processes in the course of inflammatory bowel disease (IBD) and participate in the bone metabolism. Interleukin 6 (IL-6) initiates osteoclastogenesis by modulating the activity of soluble receptor activator of nuclear factor kappa B ligand (sRANKL) and osteoprotegerin.
Objectives. The aim of the study was to evaluate bone mineral density (BMD) by densitometry and the concentration of interleukin 6, osteoprotegerin (OPG) and sRANKL protein (sRANKL) by ELISA in patients with IBD in relation to the control group; to assess the relationship between IL-6, OPG, sRANKL and BMD; and to assess the impact of disease duration and number hospitalization on BMD.
Material and Methods. The studied group included 37 patients with Crohn’s disease (I – CD), 37 patients with ulcerative colitis (II – UC) and 37 healthy subjects – control group (III – CG).
Results. The prevalence of osteoporosis and osteopenia was as follows: in I – CD, 18.92% and 32.43% in L2–L4; 13.51% and 35.13% in the neck, and in II – UC, 2.7% and 37.84% in L2–L4; 2.7%, and 29.73% in the femoral neck. The concentration of IL-6 correlated negatively with T-scores in the neck for the whole group, and in group I – CD, there was a significant positive correlation between serum OPG and IL-6.
Conclusion. The incidence of osteopenia and osteoporosis in patients with IBD is high and increases with the duration of the disease and the number of hospitalizations. Patients with CD are at a higher risk of skeletal pathology than patients with UC. IL-6 can modulate bone mineral density in the femoral neck especially in the course of CD.

Key words

cytokines, osteoporosis, inflammatory bowel disease

References (23)

  1. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol. 2011;7(4):235–241.
  2. Krela-Kaźmierczak I, Szymczak A, Łykowska-Szuber L, et al. Osteoporosis in gastrointestinal diseases. Adv Clin Exp Med. 2016;1:
  3. American Gastroenterological Association medical position statement: Guidelines on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:791–794.
  4. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002;13:357–368.
  5. Schulte CMS, Goebell H, Rõher HD, et al. Genetic determinants of IL-6 expression levels do not influence bone loss in inflammatory bowel disease. Dig Dis Sci. 2001;46(11):2521–2528.
  6. Park JY, Pillinger MH. Interleukin-6 in the pathogenesis of rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2007;65(1):4–10.
  7. Ito H. Novel therapy for Crohn’s disease targeting IL-6 signaling. Expert Opin Ther Targets. 2000;8(4):287–294.
  8. Sylvester AF. Effects of inflammatory bowel diseases on bone metabolism. IBMS Bonekey. 2009;6(11):420–428.
  9. Boubaker J, Feki M, Hsairi M, et al. Osteoporosis and inflammatory bowel disease: Prevalence and risk factors in Tunisian patients. Gastroenterol Clin Biol. 2003;27(10):901–907.
  10. Shirazi KM, Somi MH, Rezaeifar P, et al. Bone density and bone metabolism in patients with inflammatory bowel disease. Saudi J Gastroenterol. 2012;18(4):241–247.
  11. Tilg H, Moschen AR, Kaser A, et al. Gut, inflammation and osteoporosis: Basic and clinical concepts. Gut. 2008;57(5):684–694.
  12. Miheller P, Muzes G, Racz K, et al. Changes of OPG and RANKL concentrations in Crohn’s disease after infliximab therapy. Inflamm Bowel Dis. 2007;13(11):1379–1384.
  13. Ali T, Lam D, Bronze MS, et al. Osteoporosis in inflammatory bowel disease. Am J Med. 2009;122(7):599–604.
  14. Hashizume M, Hayakawa N, Mihara M. IL-6 trans-signaling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17. Rheumatology. 2008;47(11):1635–1640.
  15. McLean RR. Proinflammatory cytokines and osteoporosis. Curr Osteoporos Rep. 2009;7(4):134–139.
  16. Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol. 1998;93(9):1483–1490.
  17. Takac B, Mihaljevic S, Stefanić M, et al. Importance of interleukin 6 in pathogenesis of inflammatory bowel disease. Coll Antropol. 2014;38(2):659–664.
  18. Manolagas SC. The role of cytokines and their receptors in bone. Ann N Y Acad Sci. 1998;840:194–204.
  19. Romas E, Martin TJ. Cytokines in the pathogenesis of osteoporosis. Osteoporos Int. 1997;7:47–53.
  20. Keen RW, Woodford-Richens KL, Lanchbury JS, et al. Allelic variation at the interleukin-1 receptor antagonist gene is associated with early postmenopausal bone loss at the spine. Bone. 1998;23:367–371.
  21. Polinska B, Matowicka-Karna J, Kemona H. Assessment of the influence of the inflammatory process on the activation of blood platelets and morphological parameters in patients with ulcerative colitis (colitis ulcerosa). Folia Histochem Cytobiol. 2011;49:119–124
  22. Allocca M, Jovani M, Fiorino G, et al. Anti-IL-6 treatment for inflammatory bowel diseases: Next cytokine, next target. Curr Drug Targets. 2013;14(12):1508–1521.
  23. Kang S, Tanaka T, Kishimoto T. Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol. 2015;27(1):21–29. doi:10.1093/intimm/dxu081